FTC Approves Final Order Imposing Conditions on Merger of Generic Drug Marketers Amneal Pharmaceutic

Federal Trade Commission press release -------- Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Amneal’s $1.45 billion acquisition of an equity share in Impax likely would be anticompetitive. According to the complaint, which was first announced in April 2018, the acquisition likely would harm current competition in U.S. markets for three generic products: desipramine hydrochloride tablets; ezetimibe and simvastatin immediate release tablets; and felbamate tablets. To learn more click on the picture below to read the release.